Moreover, it was shown that, in a breast cancer mouse model, tranilast treatment upregulates p53 and induces PARP and CASP3 cleavage in in vitro, consistent with the promotion of tumor cell apoptosis (Subramaniam et al., 2010). This evidence concerns the gene CASP3 and breast carcinoma.